Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long term management of patients with thromboembolic disease. However, these agents have a slow onset of action which requires bridging therapy with heparin and its analogues, which are available only…
The new oral anti-coagulants and the phase 3 clinical trials
No comments:
Post a Comment